186497-72-3

Upstream product

• 23632-41-9 (E)-3-(4-bromophenyl)-2-methylacrylaldehyde 
• 66735-01-1 3-(4-bromophenyl)-2-methylpropanoic acid 
• 67-56-1 methanol 
• 25574-11-2 3-(4-bromophenyl)propanol 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 246529-83-9 rac-3-(4-bromophenyl)-2-methylpropanal 
• 213208-73-2 (5R)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-1H-imidazole-2,4(3H,5H)-dione 
• 848149-43-9 (R)-3-(4-bromophenyl)-2-(1,2-bis(benzyloxycarbonyl)hydrazinyl)-2-methylpropanoic acid 
• 848149-45-1 (R)-methyl 3-(4-bromophenyl)-2-(1,2-bis(benzyloxycarbonyl)hydrazinyl)-2-methylpropanoate 
• 848149-47-3 (R)-methyl 3-(4-bromophenyl)-2-methyl-2-(1-benzyloxycarbonyl-2-(2,2,2-trifluoroacetyl)hydrazinyl)propanoate 
• 848149-41-7 (R)-3-(4-bromophenyl)-2-(1,2-bis(benzyloxycarbonyl)hydrazinyl)-2-methylpropanal 
• 848149-49-5 (R)-methyl 2-(benzyloxycarbonylamino)-3-(4-bromophenyl)-2-methylpropanoate 
• 321901-73-9 (R)-α-methyl-4-bromophenylalanine methyl ester 

Relevant academic research and scientific papers

C -Methylation of Alcohols, Ketones, and Indoles with Methanol Using Heterogeneous Platinum Catalysts

A versatile, selective, and recyclable heterogeneous catalytic method for the methylation of C-H bonds in alcohols, ketones, and indoles with methanol under oxidant-free conditions using a Pt-loaded carbon (Pt/C) catalyst in the presence of NaOH is reported. This catalytic system is effective for various methylation reactions: (1) the β-methylation of primary alcohols, including aryl, aliphatic, and heterocyclic alcohols, (2) the α-methylation of ketones, and (3) the selective C3-methylation of indoles. The reactions are driven by a borrowing-hydrogen mechanism. The reaction begins with the dehydrogenation of the alcohol(s) to afford aldehydes, which subsequently undergo a condensation reaction with the nucleophile (aldehyde, ketone, or indole), followed by hydrogenation of the condensation product by Pt-H species to yield the desired product. In all of the methylation reactions explored in this study, the Pt/C catalyst exhibits a significantly higher turnover number than other previously reported homogeneous catalytic systems. Moreover, it is demonstrated that the high catalytic activity of Pt can be rationalized in terms of the adsorption energy of hydrogen on the metal surface, as revealed by density functional theory calculations on different metal surfaces.

Total synthesis of LFA-1 antagonist BIRT-377 via organocatalytic asymmetric construction of a quaternary stereocenter

(Chemical Equation Presented) A catalytic route for enantioselective total synthesis of cell adhesion inhibitor BIRT-377 is described. The quaternary stereocenter was constructed through L-proline-derived, tetrazole-catalyzed direct asymmetric α-amination

Substituted biphenylsulfonamide endothelin antagonists

Compounds of the formula inhibit the activity of endothelin. The symbols are defined as follows: R2 and R3 are each independently (a) hydrogen; (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z1, Z2 and Z3; (c) halo; (d) hydroxyl; (e) cyano; (f) nitro; (g) -C(O)H or -C(O)R6; (h) -CO2H or -CO2R6; (i) -SH, -S(O)nR6, -S(O)m-OH, -S(O)m-OR6, -O-S(O)m-R6, -O-S(O)mOH or -O-S(O)m-OR6; (j) -Z4-NR7R8; or (k) -Z4-N(R11)-Z5-NR9R10; and the remaining symbols are as defined in the specification.

Heterocyclic compounds

The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.

N-Isoxazolyl-biphenylsulfonamide derivatives, their preparation and their use as endothelin antagonists

A compound of the formula I an enantiomer, diastereomer or pharmaceutically acceptable salt thereof, wherein: one of X and Y is N and the other is O; R2,R3,R4 and R5 are each independently (a) hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z1, Z2 and Z3;(c) halo;(d) hydroxyl;(e) cyano;(f) nitro;(g)-C(O)H or-C(O)R6;(h)-CO2H or-CO2R6;(i)-SH,-S(O)nR6 ,-S(O)m-OH,-S(O)m-OR6,-O-S(O)m-R6,-O-S(O)mOH or-O-S(O)m-OR6;(j)-Z4-NR7R8; or(k)-Z4-N(R11)-Z5-NR9 R10; R4 and R5 together are alkylene or alkenylene, either of which may be substituted with Z1,Z2 and Z3, completing a 4-to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached; G1 is (a) hydrogen; or(b) alkyl; G2 is (a) hydroxyalkyl;(b)-(CH2)mOR6; or(c)-(CH2)m-NR12 R13;(d) mono-to hexa-halo substituted alkyl; or(e)-(CH2)n OR14; and the remaining symbols are as defined in the description.The compounds of formula I are antagonists of ET-1, ET-2 and /or ET-3 and are useful in treatment of conditions associated with increased ET levels (e.g., dialysis, trauma and surgery) and of all endothelin-dependent disorders. They are thus inter alia useful as antihypertensive agents.